Evidence map›Paper›PMID 29520442›Full record

ArticleJournal of cancer research and clinical oncology2018

CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer.

Soo Jung Lee, Sun-Young Jun, In Hee Lee, Byung Woog Kang, Su Yeon Park, Hye Jin Kim, Jun Seok Park, Gyu-Seog Choi, Ghilsuk Yoon, Jong Gwang Kim

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 5 pooled it
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 5 syntheses or guidelines pooled it, 94 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Immunotherapy in endometrial cancer.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2023
    Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Soo Jung LeeDepartment of Oncology/Hematology, Kyungpook National University Hospital, Daegu, South Korea.
Sun-Young JunDepartment of Pathology, Incheon St. Mary's Hospital, The Catholic University of Korea, Incheon, South Korea.
In Hee LeeDepartment of Oncology/Hematology, Kyungpook National University Hospital, Daegu, South Korea.
Byung Woog KangDepartment of Oncology/Hematology, Kyungpook National University Hospital, Daegu, South Korea.
Su Yeon ParkDepartment of Surgery, Kyungpook National University Medical Hospital, Daegu, South Korea.
Hye Jin KimDepartment of Surgery, Kyungpook National University Medical Hospital, Daegu, South Korea.
Jun Seok ParkDepartment of Surgery, Kyungpook National University Medical Hospital, Daegu, South Korea.
Gyu-Seog ChoiDepartment of Surgery, Kyungpook National University Medical Hospital, Daegu, South Korea.
Ghilsuk YoonDepartment of Pathology, Kyungpook National University Hospital, Daegu, South Korea. gsyoon@knu.ac.kr.
Jong Gwang KimDepartment of Oncology/Hematology, Kyungpook National University Hospital, Daegu, South Korea. jkk21c@knu.ac.kr.
Kyungpook National University · KRKyungpook National University Hospital · KRIncheon St. Mary's Hospital · KR

Funding

National Research Foundation of Korea 2014R1A5A2009242
6 · The paper itself

Abstract

purposeThis study attempted to reveal the prognostic impact of microsatellite instability-high (MSI-H) colon cancer with tumor-infiltrating immune cells (TIICs) and immune checkpoint protein expression, which are good candidates for immunotherapy. MATERIALS AND

methodsThe study included 89 patients with MSI-H colon cancer who underwent curative surgery at Kyungpook National University Chilgok Hospital. The expression status of specific inhibitory receptors, such as CD274 (programmed death-ligand 1, PD-L1), PDCD1 (programmed cell death 1, PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA4), lymphocyte-activation gene 3 (LAG3), and indolamine 2'3'-dioxygenase 1 (IDO1), was retrospectively analyzed using immunohistochemistry (IHC).

resultsAmong the 89 patients, CD274, LAG3, and IDO1 expressions in TIICs were observed in 68.6% (61 cases), 13.5% (12), and 28.1% (25) of patients, respectively. Meanwhile, CD274, CTLA4, and IDO1 were expressed in tumor cells of 24.7% (22 cases), 4.5% (4), and 72.0% (64) of patients, respectively. During the median follow-up duration of 39 months, 14 (15.7%) patients experienced disease recurrence. Among the five immune checkpoint proteins, CD274, LAG3, and IDO1 expressions in TIICs were significantly associated with a better disease-free survival (DFS) in a univariate analysis (P = 0.028, 0.037, and 0.030 respectively). Moreover, co-expression of CD274, LAG3, and IDO1 in TIICs showed an even better survival for DFS (P = 0.010). In a multivariate survival analysis, CD274, LAG3, and IDO1 expressions in TIICs remained as independent prognostic factors for a better DFS.

conclusionCD274, LAG3, and IDO1 expressions in TIICs showed a better prognosis for patients with MSI-H colon cancer. Thus, the potential therapeutic implications of these immune checkpoint molecules should be further investigated.

Indexed as

AdultAgedAged, 80 and overAntigens, CDB7-H1 AntigenBiomarkers, TumorColonic NeoplasmsFemaleHumansImmunohistochemistryIndoleamine-Pyrrole 2,3,-DioxygenaseLymphocyte Activation Gene 3 ProteinLymphocytes, Tumor-InfiltratingMaleMicrosatellite InstabilityMiddle AgedAntigens, CDB7-H1 AntigenBiomarkers, TumorCD274 protein, humanIDO1 protein, humanIndoleamine-Pyrrole 2,3,-DioxygenaseLag3 protein, humanLymphocyte Activation Gene 3 ProteinColorectal cancerImmune checkpoint moleculesMicrosatellite instabilityPrognosisTumor-infiltrating immune cells

Identifiers

PMID29520442
PMCPMC11813403
OpenAlexW2793371156

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.